Drugs / MK-7162
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03364049 | Dec 2017 → Oct 2020 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03364049 ↗ |
| Route | Oral | “oral tablets” NCT03364049 ↗ |